Loading organizations...
LongRiver Investments is a venture capital firm headquartered in Shanghai, China. The firm is committed to driving innovation and growth, primarily focusing its investment activities within the healthcare and technology sectors. It specializes in venture capital and private equity investments, aiming to identify and support promising companies.
The firm's strategic approach involves backing early-stage technology startups. LongRiver Investments leverages its capital, including its recently closed inaugural fund, to foster advancements and scale innovative solutions across its target industries, contributing to the development of the venture ecosystem.
Key people at LongRiver Investments.
LongRiver Investments is headquartered in Shanghai, China.
Key people at LongRiver Investments.
LongRiver Investments is a venture capital firm based in Shanghai, China. The firm is dedicated to fostering innovation and growth through its strategic investments. It primarily focuses on the dynamic healthcare and technology sectors, identifying opportunities to support companies that are developing groundbreaking solutions.
The firm's investment strategy encompasses both venture capital and private equity, with a particular emphasis on early-stage technology startups. LongRiver Investments seeks to provide capital and strategic guidance to these nascent companies, helping them navigate the challenges of growth and market entry. This approach is designed to cultivate a portfolio of high-potential enterprises.
LongRiver Investments successfully closed its inaugural fund, raising an impressive $385 million. This capital is deployed to support its investment mandate, enabling the firm to make significant contributions to its target sectors. The closure of this fund underscores the firm's capacity to mobilize substantial resources for its investment activities.
The firm's mission extends beyond capital provision; it aims to be a catalyst for innovation. By investing in healthcare, LongRiver Investments supports advancements that can improve patient outcomes and transform medical practices. In technology, it backs ventures that are pushing the boundaries of digital transformation and scientific discovery.
LongRiver Investments plays a role in the venture ecosystem by identifying and nurturing companies that can drive future economic growth and societal benefit. Its focus on specific, high-growth sectors allows it to develop deep expertise and provide specialized support to its portfolio companies, reinforcing its position as a key investor in these areas.
LongRiver Investments has 6 tracked investments across 5 companies. The latest tracked deal is $35.0M Seed in Spurious in January 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 30, 2026 | Spurious | $35.0M Seed | Highlight Capital | Biotrack Capital, Hankang Capital, InnoPinnacle Fund, Lichen Capital |
| Dec 23, 2025 | Worg Pharmaceuticals | $42.6M Series D | — | Wuxi Guolian Jintou Zhiyuan |
| Jun 14, 2024 | Ronovo Surgical | $41.3M Series B | Weicheng Capital, MA Jiali | King Star MED |
| Mar 1, 2023 | Allorion Therapeutics | $50.0M Series B | INCE Capital, Chen KAN | Amino Capital, SUE XU, 3sbio, Octagon Capital, WEI Cheng |
| Aug 1, 2022 | Sironax | $200.0M Series B | Gaorong Capital, Xiao (albert) Huang | F Prime Capital, ABU Dhabi Investment Authority, ARCH Venture Partners, CBC Group, Eight Roads Ventures, F Prime Capital, Future Innovation Fund, Invus, K2 Venture Partners, LSV Capital, MSA Capital, Superstring Capital, Temasek |
| Jan 1, 2020 | Ronovo Surgical | $26.0M Series B Extension | LIN Xianghong | GGV Capital, Kington Capital, Lilly Asia Ventures, Matrix Partners China, Vivo Capital |
